10.91
price up icon35.36%   2.85
pre-market  Pre-market:  10.59   -0.32   -2.93%
loading
Jaguar Health Inc stock is traded at $10.91, with a volume of 2.97M. It is up +35.36% in the last 24 hours and up +101.66% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$8.06
Open:
$8.22
24h Volume:
2.97M
Relative Volume:
36.71
Market Cap:
$3.79M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.6741
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+98.00%
1M Performance:
+101.66%
6M Performance:
-60.68%
1Y Performance:
-95.72%
1-Day Range:
Value
$8.22
$15.48
1-Week Range:
Value
$5.52
$15.48
52-Week Range:
Value
$4.02
$540.00

Jaguar Health Inc Stock (JAGX) Company Profile

Name
Name
Jaguar Health Inc
Name
Phone
415-371-8300
Name
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Name
Employee
49
Name
Twitter
@Jaguar_Health
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JAGX
Jaguar Health Inc
10.91 3.79M 10.48M -37.74M -29.03M -16.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-07-21 Initiated Cantor Fitzgerald Overweight
Jul-11-17 Initiated Rodman & Renshaw Buy

Jaguar Health Inc Stock (JAGX) Latest News

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus

Apr 25, 2025
pulisher
Apr 17, 2025

Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Jaguar Health to discuss breast cancer treatment with FDA - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan

Apr 15, 2025
pulisher
Apr 08, 2025

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com

Apr 08, 2025
pulisher
Apr 08, 2025

Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan

Apr 08, 2025
pulisher
Apr 06, 2025

Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 05, 2025

Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 02, 2025

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Jaguar Health completes $3.4 million private placement - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa

Mar 31, 2025

Jaguar Health Inc Stock (JAGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):